A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer
This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy
SCLC,Extensive Stage
DRUG: Adebrelimab
Safety (Occurrence of â‰¥ Grade 3 AE), The incidence of grade 3 or higher adverse events, End of each cycle (each cycle is 28 days)
PFS, Progression free survival, End of every two cycles (each cycle is 28 days)|ORR, Objective response rate, End of every two cycles (each cycle is 28 days)|OS, Overall survival, End of every two cycles (each cycle is 28 days)|DCR, Disease control rate, End of every two cycles (each cycle is 28 days)
This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy